PUMA BIOTECHNOLOGY, INC.
Tremor tracks 3 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- PBYIPuma Biotechnology, Inc.0Calm
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
Signing up patientsPhase 250 patientsMain results: Mar 31, 2028 - PBYIPuma Biotechnology, Inc.0Calm
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Signing up patientsPhase 2225 patientsMain results: Dec 30, 2027 - PBYIPuma Biotechnology, Inc.0Calm
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Signing up patientsPhase 2120 patientsMain results: Oct 30, 2027
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
10 sales (0 not pre-planned) · 0 purchases
- WILSON TROY EDWARDBoard member · Sep 14, 2026Sold 5,000 sharesabout $46 thousand · pre-planned
- Cesano AlessandraBoard member · Sep 14, 2026Sold 62,150 sharesabout $567 thousand · pre-planned
- AUERBACH ALAN HPresident and CEO · Jul 6, 2026Sold 44,058 sharesabout $364 thousand · pre-planned
- HUNT DOUGLAS MSee Remarks · Jul 6, 2026Sold 8,460 sharesabout $70 thousand · pre-planned
- NOUGUES MAXIMO FChief Financial Officer · Jul 6, 2026Sold 9,386 sharesabout $78 thousand · pre-planned
- WILSON TROY EDWARDBoard member · Jun 12, 2026
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.